Dichloroisoprenaline

Dichloroisoprenaline
File:Dichloroisoprenaline.svg
Preferred IUPAC name Dichloroisoprenaline
Systematic name 1-(3,4-Dichlorophenyl)-2-[(propan-2-yl)amino]ethan-1-ol
Other names 1-(3,4-Dichlorophenyl)-2-(isopropylamino)ethanol Dichlorisoproterenol
style="background: #F8EABA; text-align: center;" colspan="2" | Identifiers
CAS number	59-61-0
PubChem	443400 (1R) Y, 6951395 (1S) Y, 5806 () Y
ChemSpider	391627 (1R) Y, 5324297 (1S) Y, 5601 () Y
KEGG	C11772
MeSH	Dichloroisoproterenol
ChEBI	144234
SMILES
InChI
InChI key	VKMGSWIFEHZQRS-UHFFFAOYSA-N
style="background: #F8EABA; text-align: center;" colspan="2" | Properties
Molecular formula	C11H15Cl2NO
Molar mass	248.15 g/mol
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

Dichloroisoprenaline (DCI), also known as dichlorosisoproterenol, was the first beta blocker ever to be developed. It is non-selective for the β₁-adrenergic and β₂-adrenergic receptors. DCI has low potency and acts as a partial agonist/antagonist at these receptors.

Although DCI was of no clinical value itself, further developments from DCI eventually led to the development of the clinical candidate pronethalol (withdrawn due to carcinogenicity) and subsequently propranolol (the first clinically-successful beta blocker).

Dichloroisoprenaline is a racemic mixture of enantiomers.

File:(±)-Dichlorosisoproterenol Enantiomers Structural Formulae.png

The two enantiomers of dichloroisoprenaline